论文部分内容阅读
[目的]探讨三维适形放疗联合化疗同步与序贯治疗Ⅲ期非小细胞肺癌(NSCLC)的疗效和不良反应。[方法]将95例Ⅲ期NSCLC患者随机分为两组:序贯治疗组及同步治疗组,两组均采用三维适形放射治疗(3D-CRT),序贯组先采用DP方案化疗,化疗2个周期后行放疗,放疗结束后再行2个周期化疗;同步组化疗与放疗同时进行,连续化疗4个周期,两组放疗方法及化疗药物和剂量均相同。[结果]序贯组治疗有效(CR+PR)率60.78%,同步组治疗有效(CR+PR)率81.81%,两组差异有显著性(P<0.05);1年生存率序贯组50.98%,同步组61.36%,差异无显著性(P>0.05);2年生存率序贯组17.65%,同步组36.36%,差异有显著性(P<0.05)。两组患者均能耐受治疗中的不良反应。[结论]三维适形放疗联合同步化疗的近期疗效及2年生存率优于对照组,患者可耐受。
[Objective] To investigate the efficacy and adverse reactions of three-dimensional conformal radiotherapy combined with chemotherapy in the treatment of stage Ⅲ non-small cell lung cancer (NSCLC). [Methods] Ninety-five patients with stage Ⅲ NSCLC were randomly divided into two groups: sequential therapy group and synchronous therapy group. Three-dimensional conformal radiotherapy (3D-CRT) was used in both groups. DP sequential chemotherapy and chemotherapy After 2 cycles of radiotherapy, radiotherapy after the end of 2 cycles of chemotherapy; simultaneous chemotherapy and radiotherapy at the same time, continuous chemotherapy 4 cycles, two groups of radiotherapy methods and chemotherapy drugs and doses are the same. [Results] The effective rate of CR + PR in sequential group was 60.78%, the effective rate of CR + PR in synchronized group was 81.81%, there was significant difference between the two groups (P <0.05). The 1-year survival rate was 50.98 %, Synchronous group was 61.36%, no significant difference (P> 0.05); 2-year survival rate was 17.65% in sequential group and synchronous group was 36.36%, the difference was significant (P <0.05). Both groups of patients were able to tolerate adverse reactions during treatment. [Conclusion] The short-term curative effect and 2-year survival rate of three-dimensional conformal radiotherapy combined with concurrent chemotherapy are better than that of the control group, and the patients are tolerant.